"ESMO 2023: Keytruda and Padcev Slash Bladder Cancer Death Risk by 50%"

At ESMO 2023, the combination of Pembrolizumab and Padcev demonstrated a groundbreaking 50% reduction in death risk for patients with muscle-invasive bladder cancer undergoing surgery.

• Pembrolizumab, developed by Merck & Co., alongside Padcev from Pfizer and Astellas, showed a 50% reduction in the death risk for muscle-invasive bladder cancer patients.
• The treatment was administered as part of a neoadjuvant therapy approach before and after surgery, marking a significant advancement in oncology for bladder cancer.
• Results from the trial suggest that this combination could replace traditional chemotherapy options like cisplatin, offering a more effective treatment pathway for patients.